PBLS Parabilis Medicines, Inc.
Fundamentals / CIK 0001657677 / USDParabilis Medicines, Inc. reported $1.13B in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open PBLS in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$871.6M Total debt: $41.83M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Revenue | $2.11M | $148K | -- | $0 | $0 | -- |
| Research & Development | $45.60M | $39.38M | -- | $28.20M | $30.13M | -- |
| Total Operating Expenses | $56.85M | $51.03M | -- | $34.84M | $36.52M | -- |
| Operating Income | -$54.74M | -$50.89M | -- | -$34.84M | -$36.52M | -- |
| EBITDA | -$54.14M | -$50.29M | -- | -$34.74M | -$36.32M | -- |
| Interest Income | $10.37M | $4.19M | -- | $711K | $1.05M | -- |
| Interest Expense | $124K | $210K | -- | $398K | $396K | -- |
| Net Income | -$44.49M | -$52.46M | -$45.32M | -$33.48M | -$34.81M | -$38.33M |
| Basic EPS | -$0.36 | -$2.32 | -- | -$21.66 | -$22.28 | -- |
| Diluted EPS | -$0.36 | -$2.32 | -- | -$21.66 | -$22.28 | -- |
| Basic Shares Outstanding | 123.6M | 28.9M | -- | 2.0M | 2.0M | -- |
| Diluted Shares Outstanding | 123.6M | 28.9M | -- | 2.0M | 2.0M | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2025-12-31 |
|---|---|---|---|
| Cash & Cash Equivalents | $521.2M | $1.09B | $27.71M |
| Short-Term Investments | $350.4M | $33.64M | $0 |
| Cash & Short-Term Investments | $871.6M | $1.12B | $27.71M |
| Accounts Receivable, Net | $443K | -- | $0 |
| Total Current Assets | $879.0M | $1.13B | $29.36M |
| Property, Plant & Equipment, Net | $9.51M | $6.72M | $6.71M |
| Long-Term Investments | $201.3M | -- | $0 |
| Total Non-Current Assets | $252.2M | $49.87M | $51.46M |
| Total Assets | $1.13B | $1.18B | $80.82M |
| Accounts Payable | $20.21M | $18.52M | $17.27M |
| Short-Term Debt | $2.00M | $5.71M | $13.08M |
| Deferred Revenue (Current) | $13.54M | $10.37M | $0 |
| Total Current Liabilities | $68.26M | $62.84M | $56.79M |
| Long-Term Debt | -- | $700K | $600K |
| Deferred Revenue (Non-Current) | $27.30M | $31.15M | $0 |
| Total Non-Current Liabilities | $58.64M | $64.69M | $40.55M |
| Total Liabilities | $126.9M | $127.5M | $97.34M |
| Total Debt (incl. Leases) | $41.83M | $48.21M | $59.30M |
| Common Stock | $12K | $12K | $0 |
| Retained Earnings | -$683.8M | -$639.3M | -$541.5M |
| Accumulated Other Comp. Income | -$1.91M | -$18K | $0 |
| Total Stockholders' Equity | $1.00B | $1.05B | -$526.5M |
| Total Equity | $1.00B | $1.05B | -$526.5M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$44.49M | -$52.46M | -$45.32M | -$33.48M | -$34.81M | -$38.33M |
| Depreciation & Amortization | $600K | $600K | -- | $100K | $200K | -- |
| Stock-Based Compensation | $2.74M | $3.63M | -- | $820K | $823K | -- |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 12.88x | 17.91x | -- | -- | -- | -- |
| Quick Ratio | 12.78x | 17.83x | -- | -- | -- | -- |
| Debt to Equity | 0.04x | 0.05x | -- | -- | -- | -- |